Related Experiment Video

Updated: Aug 9, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

[Impaired glucose metabolism in patients with ischaemic heart disease]

M Leschke1, B Schwenk, C Bollinger

  • 1Klinik für Kardiologie, Pneumologie und Angiologie, Arztlicher Direktor, Städtische Kliniken Esslingen, Hirschlandstr. 97, 73730 Esslingen, Germany. m.leschke@kliniken-es.de

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|April 7, 2006
PubMed

Insights

Patients with heart disease often have impaired glucose tolerance. Managing blood sugar early can reduce cardiovascular deaths in diabetics and those with prediabetes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Context:

  • Ischaemic heart disease (IHD) frequently coexists with impaired glucose tolerance (IGT).
  • The 75-75 rule highlights high cardiovascular mortality in diabetics and IGT prevalence in myocardial infarction (MI) patients.
  • Existing data confirm elevated mortality post-STEMI and NSTEMI in diabetic patients, especially women.

Purpose:

  • To analyze the correlation between blood glucose levels and mortality during acute myocardial infarction.
  • To investigate the role of early glucose control interventions in reducing cardiovascular mortality.
  • To confirm the higher mortality rates in diabetic patients following myocardial infarction.

Summary:

  • Elevated blood glucose during acute MI correlates with increased mortality, stemming from pre-existing diabetes or metabolic syndrome, or indicating extensive myocardial damage.
  • Intensive glucose control strategies have shown potential in reducing cardiovascular risk, including sudden cardiac death.
  • Early intervention targeting normalization of glucose control in prediabetic individuals is crucial for mitigating cardiovascular mortality.

Impact:

  • Highlights the critical link between glucose metabolism and cardiovascular outcomes.
  • Emphasizes the need for proactive management of glucose levels in IHD patients.
  • Supports the implementation of early glucose-lowering interventions to improve survival rates in patients with or at risk of diabetes and heart disease.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...